Enterprise Value

5.647B

Cash

383.8M

Avg Qtr Burn

-121.5M

Short % of Float

16.55%

Insider Ownership

6.24%

Institutional Own.

95.46%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
NULIBRY (Fosdenopterin) (BBP-870/ORGN001) Details
Molybdenum cofactor deficiency type A

Approved

Quarterly sales

Acoramidis (AG10) Details
Transthyretin Amyloid Cardiomyopathy

NDA

Submission

BBP-418 Details
Limb-Girdle Muscular Dystrophy

Phase 3

Data readout

Encaleret Details
Autosomal Dominant Hypocalcemia Type 1

Phase 3

Data readout

Infigratinib Details
Achondroplasia

Phase 3

Initiation

BBP-631 Details
Congenital adrenal hyperplasia

Phase 1/2

Data readout

BBP-398 + OPDIVO Details
Solid tumor/s, Non-small cell lung carcinoma, Lung cancer

Phase 1/2

Data readout

BBP- 812 Details
Canavan disease

Phase 1/2

Update

Failed

Discontinued